hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fludrocortisonefludrocortisone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fluphenazinetriazolam and fluphenazine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and triazolam both increase sedation. Use Caution/Monitor.fluvoxaminefluvoxamine will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.formoteroltriazolam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fosamprenavirfosamprenavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosaprepitantfosaprepitant will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosphenytoinfosphenytoin will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.gabapentingabapentin, triazolam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilgabapentin enacarbil, triazolam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.ganaxolonetriazolam and ganaxolone both increase sedation. Use Caution/Monitor.glofitamabglofitamab, triazolam. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glofitamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .glycerol phenylbutyrateglycerol phenylbutyrate will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index.grapefruitgrapefruit will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.griseofulvingriseofulvin will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.haloperidoltriazolam and haloperidol both increase sedation. Use Caution/Monitor.hydrocortisonehydrocortisone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.hydromorphonetriazolam and hydromorphone both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and triazolam both increase sedation. Use Caution/Monitor.iloperidonetriazolam and iloperidone both increase sedation. Use Caution/Monitor.iloperidone increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.imipraminetriazolam and imipramine both increase sedation. Use Caution/Monitor.indinavirindinavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isavuconazonium sulfateisavuconazonium sulfate will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isoniazidisoniazid will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isoproterenoltriazolam increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.istradefyllineistradefylline will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.ketamineketamine and triazolam both increase sedation. Use Caution/Monitor.ketotifen, ophthalmictriazolam and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.lapatiniblapatinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.larotrectiniblarotrectinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lasmiditanlasmiditan, triazolam. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lenacapavirlenacapavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.levalbuteroltriazolam increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levonorgestrel oral/ethinylestradiol/ferrous bisglycinatelevonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of triazolam by decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines.levorphanoltriazolam and levorphanol both increase sedation. Use Caution/Monitor.lisdexamfetaminetriazolam increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lofepraminetriazolam and lofepramine both increase sedation. Use Caution/Monitor.lofexidinetriazolam and lofexidine both increase sedation. Use Caution/Monitor.lonapegsomatropinlonapegsomatropin will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Limited published data indicate that growth hormone treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance. Caution with sensitive CYP substratesloprazolamloprazolam and triazolam both increase sedation. Use Caution/Monitor.lorazepamlorazepam and triazolam both increase sedation. Use Caution/Monitor.lormetazepamlormetazepam and triazolam both increase sedation. Use Caution/Monitor.loxapinetriazolam and loxapine both increase sedation. Use Caution/Monitor.loxapine inhaledtriazolam and loxapine inhaled both increase sedation. Use Caution/Monitor.lumefantrinelumefantrine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lurasidonelurasidone, triazolam. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilinetriazolam and maprotiline both increase sedation. Use Caution/Monitor.marijuanamarijuana will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.triazolam and marijuana both increase sedation. Use Caution/Monitor.melatonintriazolam and melatonin both increase sedation. Use Caution/Monitor.meperidinetriazolam and meperidine both increase sedation. Use Caution/Monitor.meprobamatetriazolam and meprobamate both increase sedation. Use Caution/Monitor.metaproterenoltriazolam increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxalonetriazolam and metaxalone both increase sedation. Use Caution/Monitor.methadonetriazolam and methadone both increase sedation. Use Caution/Monitor.methamphetaminetriazolam increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methocarbamoltriazolam and methocarbamol both increase sedation. Use Caution/Monitor.methylenedioxymethamphetaminetriazolam increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methylprednisolonemethylprednisolone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.metronidazolemetronidazole will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.miconazole vaginalmiconazole vaginal will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.midazolammidazolam and triazolam both increase sedation. Use Caution/Monitor.midazolam intranasalmidazolam intranasal, triazolam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.midodrinetriazolam increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.mirtazapinetriazolam and mirtazapine both increase sedation. Use Caution/Monitor.mitotanemitotane decreases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.modafiniltriazolam increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.morphinetriazolam and morphine both increase sedation. Use Caution/Monitor.motherworttriazolam and motherwort both increase sedation. Use Caution/Monitor.moxonidinetriazolam and moxonidine both increase sedation. Use Caution/Monitor.nabilonetriazolam and nabilone both increase sedation. Use Caution/Monitor.nalbuphinetriazolam and nalbuphine both increase sedation. Use Caution/Monitor.nelfinavirnelfinavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nevirapinenevirapine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nifedipinenifedipine will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nilotinibnilotinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.norepinephrinetriazolam increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.nortriptylinetriazolam and nortriptyline both increase sedation. Use Caution/Monitor.olanzapinetriazolam and olanzapine both increase sedation. Use Caution/Monitor.oliceridineoliceridine, triazolam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.omaveloxoloneomaveloxolone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Omaveloxolone may reduce systemic exposure of sensitive CYP3A4 substrates. Check prescribing information of substrate if dosage modification is needed. opium tincturetriazolam and opium tincture both increase sedation. Use Caution/Monitor.orphenadrinetriazolam and orphenadrine both increase sedation. Use Caution/Monitor.oxazepamoxazepam and triazolam both increase sedation. Use Caution/Monitor.oxcarbazepineoxcarbazepine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.oxycodonetriazolam and oxycodone both increase sedation. Use Caution/Monitor.oxymorphonetriazolam and oxymorphone both increase sedation. Use Caution/Monitor.palbociclibpalbociclib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The dose of sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced if coadministered with palbociclibpaliperidonetriazolam and paliperidone both increase sedation. Use Caution/Monitor.papaveretumtriazolam and papaveretum both increase sedation. Use Caution/Monitor.papaverinetriazolam and papaverine both increase sedation. Use Caution/Monitor.pentazocinetriazolam and pentazocine both increase sedation. Use Caution/Monitor.pentobarbitalpentobarbital will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.pentobarbital and triazolam both increase sedation. Use Caution/Monitor.perphenazinetriazolam and perphenazine both increase sedation. Use Caution/Monitor.phendimetrazinetriazolam increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenobarbitalphenobarbital will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.phenobarbital and triazolam both increase sedation. Use Caution/Monitor.phenterminetriazolam increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrinetriazolam increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrine POtriazolam increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .phenytoinphenytoin will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.pholcodinetriazolam and pholcodine both increase sedation. Use Caution/Monitor.pimozidetriazolam and pimozide both increase sedation. Use Caution/Monitor.pirbuteroltriazolam increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.pirtobrutinibpirtobrutinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Pirtobrutinib (a CYP3A4 inhibitor) may increase plasma concentrations of sensitive CYP3A4 substrate which may increase the risk of adverse reactions related to these substrates. pitolisantpitolisant will decrease the level or effect of triazolam by Other (see comment). Use Caution/Monitor. Pitolisant is a borderline/weak inducer of CYP3A4. Monitor sensitive CYP3A4 substrates for reduced effectiveness if coadministered.posaconazoleposaconazole will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.prednisoneprednisone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.pregabalinpregabalin, triazolam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.primidoneprimidone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.primidone and triazolam both increase sedation. Use Caution/Monitor.prochlorperazinetriazolam and prochlorperazine both increase sedation. Use Caution/Monitor.promethazinepromethazine and triazolam both increase sedation. Use Caution/Monitor.propofolpropofol and triazolam both increase sedation. Use Caution/Monitor.propylhexedrinetriazolam increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.protriptylinetriazolam and protriptyline both increase sedation. Use Caution/Monitor.quazepamquazepam and triazolam both increase sedation. Use Caution/Monitor.quetiapinetriazolam and quetiapine both increase sedation. Use Caution/Monitor.quinupristin/dalfopristinquinupristin/dalfopristin will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ramelteontriazolam and ramelteon both increase sedation. Use Caution/Monitor.remimazolamremimazolam, triazolam. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.ribociclibribociclib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution if ribociclib is coadministered with sensitive CYP3A4 substrates that have a narrow therapeutic index. Dose reduction for sensitive CYP3A4 substrates may be needed.rifapentinerifapentine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.risperidonetriazolam and risperidone both increase sedation. Use Caution/Monitor.ritlecitinibritlecitinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Ritlecitinib inhibits CYP3A4 substrates; coadministration increases AUC and peak plasma concentration sensitive substrates, which may increase risk of adverse reactions. Additional monitoring and dosage adjustment may be needed in accordance with product labeling of CYP3A substrates. ritonavirritonavir will increase the level or